retatrutide dosing trials for weight loss: Study shows 30% body weight loss Trial Data Dosing Schedule :

At 24 weeks, liver-fat content (measured by non-invasive imaging, MRI-PDFF) fell by 81.4% on 8 mg and 82.4% on 12 mg, compared with a small increase in those participants on the placebo

Nature 429, 184187

Studies have found that higher doses can further reduce glycosylated hemoglobin and body weight, and the safety is similar to low doses

***Based on a 6-month clinical trial (n=180) of individuals who were enrolled between FebruaryApril 2024, with overweight or obesity taking semaglutide or tirzepatide for weight loss and related outcomes through the WW Clinic Program and participating in the GLP-1 companion nutrition program